Egetis Q2: Great progress both in Europe and in the US - Redeye
Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study and securing a Breakthrough Therapy Designation providing improved FDA access, which is confirmed in the upcoming pre-NDA meeting.
ANNONS
Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study and securing a Breakthrough Therapy Designation providing improved FDA access, which is confirmed in the upcoming pre-NDA meeting.